New drug combo shows promise for tough thyroid cancers, but trial ends early
Disease control
Terminated
This study tested a combination of two immunotherapy drugs (durvalumab and tremelimumab) in 79 people with advanced thyroid cancer that had stopped responding to standard treatments. The goal was to see if the drugs could shrink tumors or slow the cancer's growth. The trial was t…
Phase: PHASE2 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Jun 17, 2026 12:03 UTC